Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,357.99 +11.00 (+0.21%) Dow
38,833.13 +34.14 (+0.09%) Nasdaq
17,182.48 +49.36 (+0.29%) Bitcoin USD
69,708.43 -79.68 (-0.11%) CMC Crypto 200
1,443.24 -3.43 (-0.24%)
RYTM Jan 2025 50.000 call
- GlobeNewswire
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications - - Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3
- GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and av
- Simply Wall St.
While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week
It hasn't been the best quarter for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shareholders, since the share price...
